Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: ASHS provides turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy. Operations are divided into two segments: Leasing (fee-per-use or revenue-sharing contracts for Gamma Knife and Proton Beam Radiation Therapy equipment) and Direct Patient Services (stand-alone facilities in Rhode Island, Peru, Ecuador, and Mexico).
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 |
|---|---|---|
| Total Revenues | $7,171,000 | $20,354,000 |
| Gross Margin | $1,586,000 (22.1%) | $4,158,000 (20.4%) |
| Operating Loss | $(344,000) | $(2,187,000) |
| Net Loss (Total) | $(329,000) | $(1,719,000) |
| Net Loss Attributable to ASHS | $(17,000) | $(922,000) |
| Diluted EPS (Attributable to ASHS) | $(0.00) | $(0.14) |
| Cash and Cash Equivalents | $5,095,000 | $5,095,000 (Balance Sheet) |
| Total Debt (Current + Long-Term) | $18,184,000 | $18,184,000 (Balance Sheet) |
| Working Capital | $3,420,000 | N/A |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue increased 2.5% QoQ and 5.6% YoY (9-month). However, the Leasing segment declined (down 5.3% QoQ, 15.4% YoY 9-month) due to lower Proton Beam Radiation Therapy (PBRT) volumes and expiring Gamma Knife contracts. Conversely, the Direct Patient Services segment grew 9.4% QoQ and 36.5% YoY (9-month), driven by the Rhode Island (RI) Acquisition and the new Puebla, Mexico facility.
- Profitability: The company reported a net loss for the nine months ended Sept 30, 2025, compared to a net income of $3.5 million in the same period in 2024. The prior year's income was significantly boosted by a $3.9 million bargain purchase gain from the RI Acquisition, which did not recur in 2025.
- Cost Structure: Operating costs increased due to the integration of acquired RI facilities and the new Puebla facility. Selling and administrative expenses decreased by 20% (9-month) compared to 2024, primarily due to lower legal and transaction costs associated with the RI Acquisition which closed in May 2024.
- Liquidity: Cash and cash equivalents decreased by $5.9 million during the nine-month period, primarily due to $9.6 million in capital expenditures for property and equipment and debt repayments.
Guidance, Outlook, Risks, and Unusual Items
- Debt Covenants: The company received a limited waiver from Fifth Third Bank regarding a failure to comply with the maximum funded debt to EBITDA ratio covenant as of June 30, 2025. The company is currently in compliance as of September 30, 2025.
- Capital Commitments: ASHS has committed to purchase two Gamma Knife Esprit systems and two LINAC systems totaling $7.9 million, with installations anticipated in 2026. Service commitments total $6.9 million.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to a material weakness regarding insufficient personnel and resources with experience to create a proper control environment. Remediation includes hiring a new CFO, a Director of Revenue Cycle Management, and additional accounting staff.
- Future Outlook: The company expects to finance future projects through its Revolving Line of Credit ($7 million capacity) and cash on hand. The Credit Agreement matures in April 2026; failure to negotiate an extension could adversely impact liquidity.
- Unusual Items: The 2024 comparative period included a non-recurring bargain purchase gain of $3.9 million related to the RI Acquisition. Excluding this, the 2025 net loss represents a deterioration in operating performance driven by lower procedure volumes.
Investor Verification Checklist
- Debt Maturity: Verify the status of negotiations for the extension of the $22 million Credit Agreement maturing in April 2026.
- Volume Trends: Monitor procedure volumes for the Leasing segment (specifically PBRT and Gamma Knife) to confirm if the decline is cyclical or structural.
- Internal Control Remediation: Assess the progress of hiring and the effectiveness of the new revenue cycle management processes to address the material weakness in internal controls.
- Capital Expenditures: Confirm the availability of financing for the $7.9 million in committed equipment purchases scheduled for 2026.
- Segment Performance: Analyze the profitability trajectory of the new Direct Patient Services facilities (RI and Puebla) to determine if they can offset the decline in the Leasing segment.